Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: New technologies and innovative designs
Davies G, Boeree M, Hermann D, Hoelscher M
PLoS medicine · 2019-07
Abstract
Geraint Davies and colleagues discuss the potential for innovative early-phase clinical trial methods and technologies to reduce risk and speed up drug development for tuberculosis.
MeSH terms
- Humans
- Tuberculosis
- Antitubercular Agents
- Treatment Outcome
- Drug Therapy, Combination
- Risk Assessment
- Risk Factors
- Research Design
- Clinical Trials, Phase II as Topic
- Clinical Trials, Phase III as Topic
- Workflow
- Patient Safety
- Drug Development